Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
                                                                                                                                                                                                                                                                                                
              
  
          
              Lymphoma
              
      
          
  
  Lymphoma
              The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
          
          
                      Lymphoma
                  
      
              
        
          
                    
  
              III
          
        
        
      
              
        
          
                    
  
              Jallouk, Andrew
          
        
        
      
              
        
          
                    
  
              NCT05605899
          
        
        
      
              
        
          
                    
  
              VICCCTT2298
          
        
        
          P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Multiple Cancer Types
Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).
          
          
                      Multiple Myeloma, 
                      Phase I
                  
      
              
        
          
                    
  
              I
          
        
        
      
              
        
          
                    
  
              Dholaria, Bhagirathbhai
          
        
        
      
              
        
          
                    
  
              NCT04960579
          
        
        
      
              
        
          
                    
  
              VICCCTTP2232